Search for a command to run...
Promoter shareholding increased significantly by 16.32% YoY and QoQ, indicating strong insider confidence in Cohance Lifesciences.
Institutional and public shareholding declined, with institutions down 6.23% YoY, suggesting potential caution among smart money despite promoter optimism.
In a sector where institutional changes are neutral, the divergence in promoter activity positions Cohance as a contrarian favorite amidst a generally stable sector.
| Category | Trend | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
1Promoter Holdings | 60% | 50.1% | 50.1% | 50.1% | 50.1% | 50.1% | 66.41% | 57.49% | |
2Public Holdings | 13.91% | 23.11% | 22.67% | 22.25% | 22.37% | 22.24% | 14.95% | 15.17% | |
3Foreign Investors | 10.14% | 9.54% | 9.8% | 10.7% | 10.84% | 11.05% | 7.23% | 6.51% | |
4Domestic Investors | 15.95% | 17.25% | 17.43% | 16.95% | 16.69% | 16.61% | 11.41% | 20.83% |